1. Home
  2. ITCI vs HSIC Comparison

ITCI vs HSIC Comparison

Compare ITCI & HSIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ITCI
  • HSIC
  • Stock Information
  • Founded
  • ITCI 2002
  • HSIC 1932
  • Country
  • ITCI United States
  • HSIC United States
  • Employees
  • ITCI N/A
  • HSIC N/A
  • Industry
  • ITCI Biotechnology: Pharmaceutical Preparations
  • HSIC Medical Specialities
  • Sector
  • ITCI Health Care
  • HSIC Health Care
  • Exchange
  • ITCI Nasdaq
  • HSIC Nasdaq
  • Market Cap
  • ITCI 8.0B
  • HSIC 8.9B
  • IPO Year
  • ITCI N/A
  • HSIC 1995
  • Fundamental
  • Price
  • ITCI $86.40
  • HSIC $70.90
  • Analyst Decision
  • ITCI Strong Buy
  • HSIC Buy
  • Analyst Count
  • ITCI 12
  • HSIC 10
  • Target Price
  • ITCI $97.00
  • HSIC $77.50
  • AVG Volume (30 Days)
  • ITCI 459.9K
  • HSIC 1.1M
  • Earning Date
  • ITCI 10-30-2024
  • HSIC 11-05-2024
  • Dividend Yield
  • ITCI N/A
  • HSIC N/A
  • EPS Growth
  • ITCI N/A
  • HSIC N/A
  • EPS
  • ITCI N/A
  • HSIC 2.70
  • Revenue
  • ITCI $564,526,000.00
  • HSIC $12,487,000,000.00
  • Revenue This Year
  • ITCI $46.60
  • HSIC $6.71
  • Revenue Next Year
  • ITCI $37.06
  • HSIC $4.52
  • P/E Ratio
  • ITCI N/A
  • HSIC $26.03
  • Revenue Growth
  • ITCI 54.31
  • HSIC N/A
  • 52 Week Low
  • ITCI $46.10
  • HSIC $60.01
  • 52 Week High
  • ITCI $84.89
  • HSIC $82.63
  • Technical
  • Relative Strength Index (RSI)
  • ITCI 73.36
  • HSIC 50.47
  • Support Level
  • ITCI $75.57
  • HSIC $70.07
  • Resistance Level
  • ITCI $79.46
  • HSIC $71.58
  • Average True Range (ATR)
  • ITCI 2.42
  • HSIC 1.32
  • MACD
  • ITCI 0.60
  • HSIC -0.09
  • Stochastic Oscillator
  • ITCI 88.13
  • HSIC 43.79

About ITCI Intra-Cellular Therapies Inc.

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

About HSIC Henry Schein Inc.

Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. The company operates in two reportable segments; health care distribution and technology & value-added services. The healthcare distribution segment is engaged in combining global dental and medical businesses and distributes consumable products, small equipment, laboratory products, and Vitamins. The technology and value-added services reportable segment provides software, technology & other value-added services to health care practitioners. The majority of revenue is derived from the health care distribution segment.

Share on Social Networks: